drugset / Trial / NCT00540618
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
RandomizedSingle-groupDouble-blindTreatment
Summary
To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.
Timeline
- Start
- 2001-09
- Primary completion
- —
- Completion
- 2003-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Siplizumab | Monoclonal antibody | 5 mg | Subcutaneous |
| Comparator | Siplizumab | Monoclonal antibody | 7 mg | Subcutaneous |